A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen

Trial Profile

A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Celecoxib (Primary) ; Ibuprofen; Naproxen
  • Indications Musculoskeletal pain; Osteoarthritis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms PRECISION
  • Sponsors Pfizer
  • Most Recent Events

    • 28 Aug 2017 Results of a sub study (n=444) published in the European Heart Journal.
    • 26 Jul 2017 Results of post hoc subgroup analyses published in the American Journal of Medicine
    • 13 Nov 2016 Primary endpoint (The first occurrence of cardiovascular death,(APTC composite endpoint)) has been met,according to the results published in the New England Journal of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top